Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 5/20 | 0.61 |
| ▸ | MAOB | P27338 | 5/20 | 0.61 |
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.57 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546005 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAOAMAOBPRKCISRD5A2 | |
| SCHEMBL1091562 | 0.96 | ALDH1A1 (0.59) | ALDH1A1MAOAMAOBPRKCISRD5A2 | |
| SCHEMBL29431442 | 0.89 | SRD5A2 (0.66) | ALDH1A1MAOAMAOBPRKCISRD5A2 | |
| SCHEMBL1275273 | 0.89 | SRD5A2 (0.66) | ALDH1A1MAOAMAOBPRKCISRD5A2 | |
| SCHEMBL29545918 | 0.86 | ALDH1A1 (0.65) | ALDH1A1MAOAMAOBPRKCISRD5A2 | |
| SCHEMBL552091 | 0.86 | ALDH1A1 (0.65) | ALDH1A1MAOAMAOBPRKCISRD5A2 | |
| SCHEMBL10193085 | 0.84 | BAZ2B (0.65) | ALDH1A1MAOAMAOBPRKCIHSD17B1 | |
| SCHEMBL9944562 | 0.84 | MAOA (0.59) | ALDH1A1MAOAMAOBPRKCISRD5A2 | |
| SCHEMBL30853876 | 0.84 | MAOA (0.59) | ALDH1A1MAOAMAOBPRKCIHSD17B1 | |
| SCHEMBL10436091 | 0.84 | MAOA (0.59) | ALDH1A1MAOAMAOBPRKCIHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024140968-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-114230457-B | 2-benzylidene tetralone derivatives, and preparation method and application thereof | 中山大学 | 2023-06-09 | — | — | CN | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
| CN-115010712-A | TDO2 inhibitors | 基因泰克公司 | 2022-09-06 | — | — | CN | disclosed |
| WO-2022148358-A1 | CYCLOHEXADIIMIDE DERIVATIVE SUBSTITUTED BY FUSED HETEROCYCLYL, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2022-07-14 | — | — | WO | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| CN-114230457-A | 2-benzylidene tetralone derivatives and preparation method and application thereof | 中山大学 | 2022-03-25 | — | — | CN | disclosed |
| US-5808080-A | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5786356-A | TREATING TYPE II DIABETES, OBESITY | ELI LILLY AND COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
| WO-1998009625-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0827746-A1 | Carbazole analogues as selective B3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1997010825-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| EP-0764640-A1 | Selective beta3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1997-03-26 | — | — | EP | disclosed |
| CN-1122577-A | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | DU PONT MERCK PHARMA (US) | 1996-05-15 | — | — | CN | disclosed |
| EP-0284359-B1 | 1,4-DISUBSTITUTED PIPERAZINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-4880809-A | HYPOTENSIVE AGENTS, AMIDE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0284359-A1 | 1,4-Disubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | ALDH1A1 1758/4885MAOA 18/4885MAOB 26/4885 |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | AADAC, ENPP2, ATXN10 | ALDH1A1 1691/4885MAOA 191/4885MAOB 149/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | ALDH1A1 1849/4885MAOA 26/4885MAOB 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.